Search

Displaying results 4751 - 4760 of 5504 in total
  1. Drug

    RP-A501

    go.drugbank.com/drugs/DB17647
    Investigational

    It is being investigated for Danon disease.[L45934]

  2. Drug

    DTX-101

    go.drugbank.com/drugs/DB17699
    Investigational

    It was previously investigated for the treatment of hemophilia B; however, the clinical development of DTX-101 was discontinued.[L46103]

  3. Drug

    Coagulin-B

    go.drugbank.com/drugs/DB17703
    Experimental

    [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation

  4. Drug

    Olenasufligene relduparvovec

    go.drugbank.com/drugs/DB16264
    Investigational

    It is an adeno-associated virus (AAV) vector that delivers a functional copy of the human SGSH gene.[L46671]

  5. Drug

    Lubazodone

    go.drugbank.com/drugs/DB09196
    Experimental

    It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.

  6. Drug

    Rolicyclidine

    go.drugbank.com/drugs/DB01549
    ExperimentalIllicit

    It also has hallucinogenic and sedative properties.

  7. Drug

    Quisqualic acid

    go.drugbank.com/drugs/DB02999
    Experimental

    Quisqualic acid is an agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium

  8. Drug

    CM4620

    go.drugbank.com/drugs/DB16466
    Investigational

    CM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and...

  9. Drug

    Amitifadine

    go.drugbank.com/drugs/DB05964
    Investigational

  10. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting (CABG), congenital cardiac defect...